Moderna, Inc. · 2026-08-12 · Importance 34 · Surprise 42
Moderna provided Immunovant with a significant upfront payment tied to its IMVT-1402 drug program. The payment is cited as a catalyst alongside anticipated pivotal data readouts for IMVT-1402. The reporting indicates that the collaboration may support Immunovant’s longer-term financial profile despite the company’s current lack of revenue.
Key facts
Capital World Investors reported a 5.6% beneficial ownership stake in Moderna representing 22,276,996 shares out of 396,786,259 outstanding shares. source
Capital World Investors holds sole voting power over 22,264,639 Moderna shares and sole dispositive power over 22,276,996 shares. source